For the Inventor, By the Inventor

Enter assignee name

Philadelphia, PA, United States of America

Ossianix, Inc.

USPTO Granted Patents = 14

EPO Patents = 2

Forward Citations = 13

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Julia Lynn Rutkowski (14 out of 14 patents)

Krzysztof Bartlomiej Wicher (9 out of 9 patents)

Pawel Stocki (8 out of 8 patents)

4. Jaroslaw Michal Szary (6 out of 6 patents)

5. Julien Häsler (5 out of 5 patents)

6. Fabrizio Comper (3 out of 3 patents)

7. Mykhaylo Demydchuk (3 out of 3 patents)

8. Aziz Gauhar (1 out of 1 patent)

9. Cyril V Privezentzev (1 out of 2 patents)

10. Julien Hasler (1 out of 1 patent)

11. Laura Thei (1 out of 1 patent)

12. Shu-Fen Coker (1 out of 1 patent)

14 patents: Sort by Forward Citations

1. 12351642 - TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers (2025-07-08),

2. 12297286 - Transferrin receptor (TFR)-selective binding peptides capable of crossing the blood brain barrier, encoding nucleic acids thereof and methods of use thereof (2025-05-13),

3. 12258414 - Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries (2025-03-25),

4. 12187805 - Type-II VNAR polypeptides which bind human TfR-1, encoding nucleic acids thereof and method of use thereof (2025-01-07),

5. 11918647 - TfR selective binding compounds and related methods (2024-03-05),

6. 11766482 - In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use (2023-09-26),

7. 11512136 - Transferrin receptor (TfR)-selective binding peptides capable of crossing the blood brain barrier and methods of use thereof (2022-11-29),

8. 11345742 - Shark VNARs for treating COVID-19 (2022-05-31),

9. 11339389 - Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds (2022-05-24),

10. 11267894 - BAFF selective binding compounds and related methods (2022-03-08),

11. 11097010 - In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use (2021-08-24),

12. 10722576 - TfR selective binding compounds and related methods (2020-07-28),

13. 10479990 - Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds (2019-11-19),

14. 10435474 - Baff selective binding compounds and related methods (2019-10-08),

Ossianix, Inc. is a biotechnology company focused on developing novel antibody therapeutics for the treatment of cancer and other diseases. Through their proprietary technology platform, Ossianix is able to create bispecific antibodies with superior targeting capabilities, allowing for more precise and effective treatment options. With a strong pipeline of potential therapeutics, Ossianix is committed to advancing the field of biopharmaceuticals and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

14 Patents

#68 in Philadelphia, PA

#791 in Pennsylvania

#21,638 in US

#40,935 in the World

Philadelphia, PA, United States of America

Ossianix, Inc.

Forward Citations = 13

12 inventors:

Julia Lynn Rutkowski (14 out of 14 patents)

Krzysztof Bartlomiej Wicher (9 out of 9 patents)

Pawel Stocki (8 out of 8 patents)

4. Jaroslaw Michal Szary (6 out of 6 patents)

5. Julien Häsler (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…